Barlow’s Research Roundup: Why market doomsayers are rarely right

Cameco reported Q1/26 adjusted EPS of C$0.47, well above the C$0.23 Scotiabank estimate and C$0.34 consensus, and adjusted EBITDA of C$509 million, 38% above estimate. Scotiabank raised its 12-month target to C$175 from C$150 and reiterated Sector Outperform, citing strong contract visibility and growing AP1000 reactor demand. The broader commentary also highlighted U.S. reshoring as a multiyear tailwind for Rockwell Automation and a generally resilient inflation/economic backdrop.

Analysis

The market is still pricing a lot of “mean reversion to normal” in industrials and quality cyclicals, but the better setup is a prolonged capex cycle driven by policy, reshoring, and automation saturation. That favors equipment suppliers with installed base leverage: once factory buildouts start, service revenue and software attach rates compound, which is why the next leg in names like ROK can be less about unit growth and more about mix, pricing, and aftermarket annuity. The second-order effect is that a multi-year U.S. manufacturing rebuild creates incremental demand for controls, sensors, power systems, and factory software across the entire automation stack, not just the headline beneficiary.

Cameco’s opportunity is more rate-driven than consensus seems to appreciate. The market often treats uranium as a commodity beta trade, but the durable driver is contract repricing into a structurally tighter utility procurement regime; if term pricing continues to reset, earnings power can inflect faster than spot suggests. The key knock-on is that nuclear fuel supply is one of the few clean-energy bottlenecks that cannot be solved quickly with incremental capital, which supports a longer duration multiple premium than most miners deserve.

The contrarian signal in the macro commentary is not that bearish calls are always wrong; it’s that the consensus repeatedly underestimates the lag between policy fear and economic adaptation. That matters because it argues for staying long businesses with real operating leverage to secular investment themes while fading crowded pessimism trades that depend on an imminent recession or policy-induced collapse. The risk is timing: these themes can rerate sharply on earnings beats, but if trade policy softens or rate cuts accelerate a broad de-risking move, the market may rotate away from expensive industrial leaders into lower-quality duration names for several months.

Key Decisions for Investors

• Add to ROK on weakness, using a 3-6 month horizon: the thesis is not just a quarter beat but a multi-year reacceleration in U.S. factory capex. Risk/reward improves if the stock pulls back 5-8% after an earnings-driven move; stop if reshoring evidence stalls for two consecutive industrial order prints.
• Go long CCO vs. short a broad materials basket (or a uranium proxy not tied to contracting strength) for 6-12 months: Cameco should benefit more from contract repricing than generic commodity exposure. Risk/reward is attractive because downside is limited by tight supply, while upside expands if term prices continue to reprice higher.
• Buy ROK/CAT industrial automation exposure on pullbacks and pair against a lower-quality cyclicals basket over 1-2 quarters: the market is likely to reward companies with pricing power and service mix as capex broadens. Cover the pair if industrial orders roll over or if valuation expands beyond historical top-quartile multiples.
• Consider a small long-duration call structure on ROK or CCO into the next two earnings cycles: use calls financed by selling out-of-the-money upside to express upside participation while limiting premium outlay. Best entry is after a post-earnings consolidation, not into momentum strength.
• Avoid chasing the most crowded ‘quality is broken’ trade for now; fade short quality only if credit spreads widen and earnings revisions turn negative across defensives. The current backdrop still supports selective quality, especially where fundamentals are tied to real capex and supply bottlenecks.